A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 143

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 143
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 209
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 994
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3134
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 574
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 488
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Personalized care approaches to hepatitis C therapy: recent advances and future directions. | LitMetric

Personalized care approaches to hepatitis C therapy: recent advances and future directions.

Expert Rev Anti Infect Ther

Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Published: April 2024

AI Article Synopsis

  • The introduction of direct-acting antivirals (DAAs) has greatly improved the treatment of chronic hepatitis C (HCV), yet there's room for better efficacy and fewer side effects.
  • This review emphasizes the importance of a personalized treatment approach, considering factors like sex, comorbidities (e.g., HIV, chronic kidney disease), and the interactions between DAAs and other medications.
  • Despite high success rates (over 90%) in clinical trials, there is still potential to enhance treatment results by closely evaluating individual patient conditions and managing the complexities of their care.

Article Abstract

Introduction: The introduction of direct-acting antivirals (DAAs) has significantly transformed the therapeutic landscape for chronic C hepatitis virus (HCV) infection. However, there is still room for further improvement in optimizing therapy efficacy and minimizing adverse effects.

Areas Covered: This review is devoted to the rationale for adopting a personalized approach to HCV therapy. Specifically, we explore the role of host-related factors, such as sex or the presence of comorbidities. We thoroughly examine the implications of commonly encountered comorbidities, including HIV infection, chronic renal disease, liver cirrhosis, and other chronic viral hepatitis infections. Additionally, we discuss the prevalent drug-to-drug interactions between DAAs and other medications, while providing guidance on their management. Finally, we investigate viral-related issues that can influence treatment outcomes, such as viral genotype, quasi-species, and the presence of resistance-associated mutations.

Expert Opinion: Despite pivotal trials demonstrating efficacy rates exceeding 90% for currently available DAA regimens, there are still opportunities to optimize therapy outcomes and tailor treatment to each patient. This can be achieved through a meticulous evaluation of the patient's specific clinical conditions and comorbidities, a vigilant approach to manage potential drug interactions, and diligent patient follow-up.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2024.2328336DOI Listing

Publication Analysis

Top Keywords

personalized care
4
care approaches
4
approaches hepatitis
4
therapy
4
hepatitis therapy
4
therapy advances
4
advances future
4
future directions
4
directions introduction
4
introduction introduction
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!